RESEARCH

Open Access

Check for updates

Efficacy and safety of prone position in COVID-19 patients with respiratory failure: a systematic review and meta-analysis

Hyeon-Jeong Lee^{1†}, Junghyun Kim^{2,3†}, Miyoung Choi¹, Won-Il Choi⁴, Joonsung Joh², Jungeun Park¹ and Joohae Kim^{2*}

Abstract

Background: Prone position has already been demonstrated to improve survival in non-COVID acute respiratory distress syndrome and has been widely performed in COVID-19 patients with respiratory failure, both in non-intubated and intubated patients. However, the beneficial effect of the prone position in COVID-19 pneumonia still remains controversial. Therefore, we aimed to evaluate the effectiveness and safety of the prone position compared with the non-prone in non-intubated and intubated COVID-19 patients, respectively.

Methods: We searched the MEDLINE, EMBASE, and Cochrane databases, as well as one Korean domestic database, on July 9, 2021, and updated the search 9 times to September 14, 2022. Studies that compared prone and non-prone positions in patients with COVID-19 were eligible for inclusion. The primary outcomes were mortality, need for intubation, and adverse events.

Results: Of the 1259 records identified, 9 randomized controlled trials (RCTs) and 23 nonrandomized studies (NRSs) were eligible. In the non-intubated patients, the prone position reduced the intubation rate compared with the non-prone position in 6 RCTs (n = 2156, RR 0.81, P = 0.0002) and in 18 NRSs (n = 3374, RR 0.65, P = 0.002). In the subgroup analysis according to the oxygen delivery method, the results were constant only in the HFNC or NIV subgroup. For mortality, RCTs reported no difference between prone and non-prone groups, but in NRSs, the prone position had a significant advantage in mortality [18 NRSs, n = 3361, relative risk (RR) 0.56, P < 0.00001] regardless of the oxygen delivery methods shown in the subgroup analysis. There was no RCT for intubated patients, and mortality did not differ between the prone and non-prone groups in NRSs. Adverse events reported in both the non-intubated and intubated groups were mild and similar between the prone and non-intubated groups.

Conclusion: For non-intubated patients with COVID-19, prone positioning reduced the risk of intubation, particularly in patients requiring a high-flow oxygen system. However, the survival benefit was unclear between the prone and non-prone groups. There was insufficient evidence to support the beneficial effects of prone positioning in intubated patients.

[†]Hyeon-Jeong Lee and Junghyun Kim have contributed equally to this work

*Correspondence: joohaekim23@gmail.com

² Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul, South Korea Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Trial registration This study was registered in the Prospective Register of Systematic Reviews on February 16, 2022 (Registration No.: CRD42022311150).

Keywords: Prone position, COVID-19, Acute respiratory distress syndrome

Background

Pulmonary involvement is common in COVID-19 patients and approximately 10–20% of hospitalized patients with COVID-19 had severe respiratory failure requiring mechanical ventilation [1]. Interventions to reduce mortality risk have been actively attempted in COVID-19 patients with respiratory failure, and the prone position is one of them.

Randomized trials and meta-analysis supported that the prone position showed favorable outcomes, including improved oxygenation, respiratory mechanics, and survival in patients with moderate-to-severe non-COVID-19 acute respiratory distress syndrome (ARDS) [2-4]. Similarly, in patients with COVID-19, several studies reported that prone positioning showed improved oxygenation [5-7] and reduced mortality [8, 9]. However, patients included in those studies varied in severity and degree of oxygen requirement, from nasal prong to mechanical ventilation. In particular, it is interesting that the awake-prone position was applied in many COVID-19 patients who were not critically ill, but had an oxygen demand and the possibility of respiratory failure. A recent meta-analysis showed that an awake-prone position reduced the risk of intubation, especially in COVID-19 patients requiring advanced respiratory support [10]. However, the result was mainly driven by one large trial, and two additional large randomized trials have been published recently. They have shown conflicting results regarding the effectiveness of prone position in patients with high-flow oxygen therapy or non-invasive ventilation [11, 12].

For intubated patients, relatively fewer studies had been performed compared to those for non-intubated patients and most studies compared oxygenation status before and after the application of prone position. Since prone positioning was considered to be performed in severe respiratory failure patients if possible, few observational studies compared outcomes of patients with and without prone position. However, the effect of prone position on mortality was inconsistent between studies [9, 13] and there has been no meta-analysis or systemic review of these comparisons.

Therefore, this study aimed to evaluate the efficacy and safety of the prone position in COVID-19 patients with respiratory failure and to analyze which prone position could be recommended among non-intubated and intubated patients, respectively.

Methods

This study followed the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [14] (Additional file 1). This study was registered in the Prospective Register of Systematic Reviews (PROSPERO) on February 16, 2022 (registration number CRD42022311150).

Eligibility criteria

The inclusion criteria were as follows: (1) population studies targeting patients with moderate-to-severe COVID-19; (2) intervention and comparator—studies comparing prone position to non-prone position; (3) outcomes—studies reporting the clinical outcomes including mortality, need for invasive mechanical ventilation, adverse events; (4) studies published after 2020; (5) study designs—randomized clinical trials (RCTs) or nonrandomized studies (NRSs) with a comparator group; and (6) full-text articles in English or Korean language. The exclusion criteria were as follows: (1) studies that did not target patients with confirmed COVID-19; (2) studies that did not compare the prone position to the non-prone position; (3) studies that did not report our outcomes of interest; and (4) duplicated studies.

Information sources and search strategy

We searched the following electronic databases: international databases (Ovid MEDLINE, Ovid EMBASE, the Cochrane Central Register of Controlled Trials), and the Korean domestic database (KMBASE) on July 9, 2021. Since new evidence on the prone position of COVID-19 patients is continuously produced, we updated the search 9 times from September 10, 2021, to September 14, 2022. We searched Ovid-MEDLINE for updates and reference lists of previously published reviews. We used Boolean operators such as (2019-nCoV OR COVID-19 OR Wuhan) AND (prone position OR prone posture OR proning). The search strategy is presented in Additional file 2.

Selection process

Four authors (HJL, JoK, JP, and JuK) independently screened the retrieved citations by title and abstract in COVIDENCE (https://www.covidence.org/) according to the inclusion and exclusion criteria. Full texts were assessed for the final decision of inclusion or exclusion by two authors (HJL and JoK). If an agreement was not

reached between the two authors, it was reached through discussion with the third author (MC).

Data items and extraction

The following data were extracted from the eligible studies using an electronic spreadsheet (Microsoft Excel) of data abstraction form: first author, published year, study design and setting, study location, sample size in each arm, oxygen therapy method, prone position protocol and duration, and outcomes of interest. Two authors (JP and JuK) extracted information from each included study, and two other authors (WIC and JJ) checked the data independently.

Study outcomes

The primary outcomes were mortality, the need for intubation (in the case of non-intubated patients), and adverse events. The secondary outcomes were the length of stay (LOS) in the hospital or intensive care unit (ICU), ICU-free days, and ventilator-free days.

Study risk-of-bias assessment

A validated tool was used according to the study design to evaluate the risk of bias in the included studies. The Cochrane risk-of-bias tool (RoB) 1.0 [15] was used for RCTs, and the Risk of Bias Assessment tool for Nonrandomized Studies (RoBANS) 2.0 [16] which was updated from RoBANS 1.0 [17] for nonrandomized studies. Two independent authors (WIC and JJ) conducted quality assessments of the studies, and disagreements were resolved by a third author (MC).

Effect measures and synthesis methods

Based on the data extraction results, the meta-analysis was performed as follows. Relative risks (RR) with 95% confidence intervals (CI) for discrete outcome data and mean differences (MD) with 95% CI for continuous outcome data were calculated using the random-effects model because of heterogeneity across studies. Statistical significance was set at P < 0.05. To assess betweenstudy heterogeneity, we displayed forest plots and calculated I^2 statistics with a value of >75%, considered high heterogeneity [18]. A subgroup analysis was performed based on oxygen delivery methods [conventional oxygen therapy (COT), high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or invasive mechanical ventilation (IMV)]. When more than one oxygen delivery method was used, the studies were classified based on the method by which the majority of patients received oxygen. To assess publication bias, we generated funnel plots for the primary outcomes reported in at least ten studies and performed Egger's Page 3 of 19

linear regression test. We used Review Manager (Rev-Man) 5.4 [19] to synthesize the data and R version 4.2.1 [20] for Egger's linear regression test.

Certainty of evidence assessment


We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) [21] to assess the certainty of the evidence of the primary outcomes. Two authors (WIC and JJ) assessed the certainty of the evidence as high, moderate, low, or very low, and discrepancies were resolved by a third author (MC).

Results

Study selection

The study selection process is illustrated in Fig. 1. A total of 1426 records were identified using the search strategy on July 9, 2021, and 347 duplicate records were removed before the screening. One hundred and eighty records were updated until September 14, 2022. Of the 1259 records, 1116 were excluded after screening using titles and abstracts. Subsequently, the full texts of the 143 reports were retrieved. After reviewing the eligibility of the original texts, 9 RCTs with 2431 patients (sample size range, 27-1121) [11, 12, 22-28] and 23 nonrandomized studies (NRSs) including 2 nonrandomized controlled trains with 744 patients (sample size range, 243-501) [29, 30], 7 prospective cohort studies with 761 patients (sample size range, 32-335) [5, 7, 31-35], and 14 retrospective cohort studies with 3119 patients (sample size range, 20-827) [6, 8, 9, 36-46] were included in our review. The list of excluded studies and reasons for exclusion are presented (Additional file 3).

The characteristics of the included studies are summarized in Table 1. Eleven studies originated in Europe [6, 8, 26, 27, 30, 32, 33, 37, 44-46], eight from Asia [5, 25, 34-36, 38, 40, 41], five from North America [9, 23, 28, 29, 39], four from the South America [11, 31, 42, 43], two from Africa [7, 24], and two from multiple countries [12, 22]. Seventeen studies [6, 8, 11, 12, 22, 23, 25, 27, 29, 31, 32, 34, 41, 43–46] were conducted at multiple centers and others at single centers. In most of the studies, including the all RCTs, patients were provided through the COT, HFNC, or NIV, and in three NRSs studies [9, 38, 45], through mechanical ventilation. The proning protocols varied in terms of time and frequency of sessions, such as at least 2–18 h per day or no restrictions in time and frequency. The reported proning durations varied. The average proning time per day (3–15 h per day) [11, 22, 26, 27, 29-31, 34, 40, 45], the total number of proning session (2-4 sessions) [11, 30, 40], or days in proning (2.5-13 days) [11, 12, 27, 30, 31, 40, 44, 45] were reported.



Risk of bias in studies

The majority of RCTs were assessed as having a low risk of bias in all the dimensions. In more than half of the NRSs, the domains of the possibility of target group comparison and selection were rated as having a high risk of bias (Additional file 4: Fig. S1). However, serious problems did not occur because the domains of exposure measurement, blinding of assessors, outcome assessment, and selective outcome reporting were assessed as having a low risk of bias in most NRSs.

Non-intubated group

Mortality

In the eight RCTs [11, 12, 22–25, 27, 28], there was no difference in morality between prone and non-prone groups (high certainty of evidence), but in the NRSs [6–8, 29–37, 39, 40, 42–44, 46], the prone position had a significant advantage of survival in the non-intubated patient group (18 NRSs, n=3361, RR 0.56, 95% CI 0.45 to 0.70, P<0.00001, $l^2=52\%$, very low certainty of evidence; Fig. 2). The subgroup analysis for the oxygen delivery method showed constant results (Figs. 3, 4). In NRSs,

prone reduced mortality compared to non-prone in the nasal cannula or facial mask group (6 NRSs, n = 1309, RR 0.57, 95% CI 0.48–0.67, P < 0.00001, $I^2 = 0\%$) and the HFNC or NIV group (6 NRSs, n = 1262, RR 0.47, 95% CI 0.31–0.71, P = 0.0003, $I^2 = 41\%$). Although the funnel plot for mortality in NRSs was asymmetric, we observed no evidence of publication bias in Egger's linear regression test (P = 0.2192, Additional file 4: Fig. S2).

Need for intubation

The intubation rate of the prone group was significantly lower than that of the non-prone group in 7 RCTs (n=2156, RR 0.81, 95% CI 0.72 to 0.90, P=0.0002, $I^2=0\%$, high certainty of evidence) [11, 12, 22, 24, 25, 27, 28] and 18 NRSs (n=3374, RR 0.65, 95% CI 0.50 to 0.85, P=0.002, $I^2=74\%$, very low certainty of evidence) [6, 29, 30, 36, 37, 39–44, 46] (Fig. 5). In the subgroup analysis according to the oxygen delivery method, proning showed advantage only in the HFNC or NIV subgroup (Figs. 6, 7). Although the funnel plot for the intubation rate of nonrandomized studies was asymmetric, we observed no evidence of publication bias in Egger's linear regression test (P=0.8453, Additional file 4: Fig. S3).

First author, published	Study design	Study setting	Study location	Enrollment period	Total sample size	Age (year, IQR or SD)	Male (%) (prone/non-	Oxygen therapy mothods	Proning protocol	Location of proning	Proning dura group	Proning duration in prone group
year					non-prone)	prone)		sponent			Daily	Total
Ehrmann [22]	RCT	Multicenter	Canada, France, Ireland, Mexico, USA, Spain	2020.4.2 2021.1.26	1121 (564/557)	61.5 (13.3)/60.7 (14.0)	67/66	HFNC	As long and as frequently as possible each day	ICU, Ward, ER	5 (IQR 1.6–8.8) h	Х
Jayakumar [25]	RCT	Multicenter	India	л Х	60 (30/30)	54.8 (11.1)/57.3 (12.1)	83.3/83.3	Nasal prongs, face mask, non- rebreather mask, HFNC, or NIV	≥ 6 h/day (cumulative)	ICU	≥ 6 h in 43% of interven- tion group	X
Kharat [26]	RCT	Single center	Switzerland	2020.4.6.– 2020.4.25	27 (10/17)	54 (14)/60 (11)	60/65	Nasal can- nula	≤12 h/day	Ward	295 (SD 216) m	NR
Rosén [27]	RCT	Multicenter	Sweden	2020.10.7 2021.2.7	75 (35/39)	66 (53–74)/65 (55–70)	64/82	HFNC, NIV	≥ 16 h/day	Ward, ICU	9.0 (IQR 4.4–10.6) h	4.2 (1.7–5.7) d
Taylor [28]	RCT	Single center	SU	2020.6.1 2020.8.31	40 (27/13)	56 (45–66)/60 (54–63)	63/77	Nasal can- nula, MFNC	As long as possible and allowed to return to the supine position as necessary	Ward	NR	х
Fralick [23]	RCT	Multicenter	Canada, US	2021.3 2021.5	248 (126/122)	59.5 (45–68)/54 (44–62)	65/63	Nasal can- nula, mask, HFNC	Four sessions/ day (up to 2 h/sessions), encouraged to sleep in pone position overnight	Ward	ИК	From rand- omization to first 72 h: 6 (1.5–12.8) h, from 72 h to 7 d: 0 (0–12) h
Gad [24]	RCT	Single center	Egypt	2020.6 2020.9	30 (15/15)	49.0 (38–62)/46.0 (33–51)	60.0/53.3	High flow with non- rebreathing facemask	Each session for 1–2 h according to patient to tolerability with 3 h apart during waking hours	Critical care isolation	х Х	R
lbarra-Estrada [11]	RCT	Multicenter	Mexico	2020.5.5 2021.1.26	430 (216/214)	58.6 (15.8)/58.2 (15.8)	61.1/58.9	HFNC	As long as possible	Intermediate or intensive care unit	4 sessions/d (3–5) 3.4 (3–3.6) h/	9.4 (5.6–12.9) h for 6 (3.7–9) ds

First author, published	Study design	Study setting	Study location	Enrollment period	Total sample size	Age (year, IQR or SD)	Male (%) (prone/non-	Oxygen therapy	Proning protocol	Location of proning	Proning dura group	Proning duration in prone group
year					(prone/ non-prone)	(prone/non- prone)	prone)	methods			Daily	Total
Alhazzani [12]	RCT	Multicenter	Multicountry	2020.5.19– 2021.5.13	400 (205/195)	56.8 (12.5)/58.3 (13.2)	73/69	HFNC, LFNC, NPPV	8 h/d–10 h/d with 2 to 3 breaks (1–2 h each), if needed	ICU or a monitored acute care unit	NR	3 (1–5) d
Musso [30]	NRCT	Single center	Italy	Int 2020.12.16.– 2021.5.30. Cont 2020.4.1.– 2020.4.1.–	243 (81/162)	68 (60–75)/69 76/72 (61–78)	76/72	NZ	As long as possible, at least 1 session/day lasting ≥ 8 h scheduled overnight	Subintensive care unit	12.2 (10.1–13.8) h, 2 session/d	6 (5–8) d
Qian [29]	NRCT	Multicenter	N	2020.5.13 2020.12.11	501 (243/258)	61.6 (15.4)/60.3 (15.2)	56.6/56.8	HFNC, LFNC, NIV	Encouraged as often and consistently as possible	NR	4.2 (1.8–6.7) h	NR
Ferrando [32]	Prospective cohort study	Multicenter	Spain, Andorra	2020.3.12 2020.6.9	199 (55/144)	60.0 (54.0– 70.0)/63.0 (55.0–71.0)	75.9/72.7	HFNC	> 16 h regard- less of the number of sessions	ICU	NR	NR
Ni [5]	Prospective cohort study	Single center	China	2020.1.31.– 2020.2.15	52 (17/35)	60 (12)/64 (12)	64.7/60	NR	≥ 4 h/day for 10 days	Provisional ICU	NR	NR
Zang [35]	Prospective cohort study	Single center	China	2020.2.1 2020.4.30	60 (23/37)	63 (59–71)/66 (60–72)	56.5/70.3	O ₂ storage mask	1–2 h/session, 3–4 sessions/ day for more than 5 con- secutive days	N	ХК	13.4 (SD 8.0) h
Bahloul [7]	Prospective cohort study	Single center	Tunisia	2020.9.1 2020.12.4	38 (21/17)	61 (10)/60 (12)	76.2/NR	Facial mask, HFNC	2–4 h fol- lowed by 2 h of supine positioning during the day, during the day, ar night, when possible	ΓC	Ř	Ř
Esperatti [31]	Prospective cohort study	Multicenter	Argentina	2020.6.– 2021.1	335 (187/148)	57 (47– 66)/66.5 /66 5	76/72	HFNC	≥ 6 h/day, no time limits for	ICU	12 (IQR 9–16) h	5 (IQR 3–8) d

Table 1 (continued)	tinued)											
First author, published	Study design	Study setting	Study location	Enrollment period	Total sample size	Age (year, IQR or SD)	Male (%) (prone/non-	Oxygen therapy	Proning protocol	Location of proning	Proning dura group	Proning duration in prone group
year					(prone/ non-prone)	(prone/non- prone)	pronej	memous			Daily	Total
Sryma [34]	Prospective cohort study	NR	India	R	45 (30/15)	50.9 (10.1)/57.5 (12.2)	96.7/60	NIV, HFNC, COT	≥ 2 h/session, target duration of 8 h/day	R	7.5 (range 4–12) h on the first day	NR
Pierucci [33]	Prospective cohort study	Single center	Italy	2020.3.11 2020.4.30	32 (16/16)	59 (11)/70 (15)	81/62	Int: spon- taneously breathing Cont: HFNC, CPAP, NIV	As long as possible with intervals for meals and other personal care			
Jagan [39]	Retrospec- tive cohort study	Single center	N	2020.3.24 2020.5.5	105 (40/65)	56.0 (14.4)/65.8 (16.3)	50/56.9	Non-intuba- tion	≥ 1 h/day for at least 5 ses- sions, ≥ 1 h/ overnight	NR	NR	NR
Padrão [42]	Retrospec- tive cohort study	Single center	Brazil	2020.3.1 2020.4.30	166 (57/109)	51.8 (13)/61.4 (13.6)	70/66	Nasal can- nula, venturi mask, non- rebreather mask	≥ 4 h in the first session, stimulated twice daily to maintain proning	щ	First ses- sion < 1 h 6%, 1–2 h 14%, 2–3 h 12%, 3–4 h 10%, > 4 h 58%	R
Barker [37]	Retrospec- tive cohort study	Single center	N	2020.3.26 2020.6.26	20 (10/10)	59 (55–63)/65 (55–71)	60/60	NIV (Int 90%, Con 70%)	30 m–2 h, repeated as many times as comfortable	ICU	NR	1 20 (IQR 76–161) m, 4 (IQR 1–7) ses- sions/patient
Jouffroy [6]	Retrospec- tive cohort study	Multicenter	France	2020.2.20 2020.4.24	379 (40/339)	59.5 (56–64)/62 (53–69)	90/75.2	HFNC	3–6 h/session, twice a day	ICU	NR	2.5 (IQR 1.6–3.4) d, 3 (IQR 2–5) ses- sions
Loureiro- Amigo [8]	Retrospec- tive cohort study (SEMI- COVID-19)	Multicenter	Spain	2020.3.1.– 2020.8.31	163 (60/103)	66.57 [59.2– 7.2.4]/70.81 [60.6–74.2]	71.7/68.9	Venturi masks, rebreathing masks	R	Ward	NR	NR
Prud'homme [44]	Retrospec- tive cohort study	Multicenter	France	2020.3.20- 2020.4.20	96 (48/48)	62 (11)/61 (18)	77.1/64.6	COT, HFNC	≥ 3 h/day dur- ing 3 consecu- tive days, 1 to 12 h/session	Non-ICU	3–8 h in 67%, > 5 h in 38% of intervention group	6.9 (SD 5.2) d

Table 1 (continued)	(panulu											
First author, published	Study design	Study setting	Study location	Enrollment period	Total sample size	Age (year, IQR or SD)	Male (%) (prone/non-	Oxygen therapy	Proning protocol	Location of proning	Proning dura group	Proning duration in prone group
year					(prone/ non-prone)	(prone/non- prone)	prone)	methods			Daily	Total
Shelhamer [9]	Retrospec- tive cohort study	Single center	N	2020.3.25 2020.5.2	261 (62/199)	60.0 (54.3– 66.5)/66.0 (55.0–74.5)	67.7/60.3	2 M	≥ 16 h in the afternoon, supine position the following morning	Traditional ICU, Con- verted floor ICU	۳	X
Stilma [45]	Retrospec- tive cohort study	Multicenter	Netherlands	2020.3.1 2020.6.1	734 (438/296)	Without indication for proning 65.0 (10.3)/64.2 (11.4) With indication for proning 62.6 (11.2)/66.6 (9.1)	72.6/73.3	NMI N	щ	ίCΩ	15.0 (IQR 10.5–21.0) h	3 (2–3) d
Tonelli [46]	Retrospec- tive cohort study	Multicenter	Italy	2020.3.1.– 2020.6.1	114 (38/76)	61 (32 – 75)/70 (33 – 80)	66/73	HFNC, CPAP, NIV	≥ 3 h before back to supine	ICU	R	NR
Perez-Nieto [43]	Retrospec- tive cohort study (APRO- NOX study)	Multicenter	Mexico, Ecuador	2020.5.1.– 2020.6.12	827 (505/322)	53.4 (13.9)/55.8 (14.5)	73.3/71.4	LFNC, HFNC or a non- rebreather mask	≥ 2 h continu- ously	ICU 13% non-ICU 87%	NR	12 (IQR 8–24) h
Koike [40]	Retrospec- tive study	Single center	napan	lnt: 2020.10.1 2020.12.1. Cont: 2020.12.1 2020.3.31	58 (27/31)	71 (55–77)/63 (49–70)	28/06	Simple O ₂ , HFNC, NPPV	Discontinued if the patient developed intolerable respiratory dis- tress, tachyp- tress, tachyp- tress, tachyp- or new unac- ceptable back pain during proning	icu	2 (2–3) sessions/d 180 (120– 240) m	13 (7–16) d
Altinay [36]	Retrospec- tive study	Single center	Turkey	2020.3.15.– 2020.6.15	48 (25/23)	62.4 (10.9)/72.6 (10.1)	44/39.1	Nonre- breather mask oxygen	18 h intermit- tently in a day	ICU	NR	NR

First author, Study published design	Study design	Study setting	Study location	Enrollment Total period samp	Total sample size	Total Age (year, sample size IQR or SD)	Male (%) (prone/non-		Proning protocol	Location of proning	Proning dı group	Location of Proning duration in prone proning group
year					(prone/ non-prone) prone)	(prone/non- prone) prone)	prone)	methods			Daily	Total
Numata [41]	Numata [41] Retrospec- tive study	Multicenter Japan	Japan	2020.7- 2021.2	108 (54/54)	108 (54/54) 68 (58–76)/70 68.5/42.6 (59–79)	68.5/42.6	HENC	As long as pos-Severe sible, at least COVID- 3 times a day patient and for at least 6 h per day	Severe COVID-19 patient unit	Х Х	NR
Chen [38]	Retrospec- tive study	Single center	China	2020.1.9 2020.4.10	40 (17/23)	69 (56–87)/72 64.7/78.3 (54–89)	64.7/78.3	N/	NR	ICU	NR	NR
RCT, randomize standard defini airway pressure	ed controlled trial tion; NR, not repc ;; LFNC, low-flow.); NRCT, nonrandc orted; NIV, non-in nasal cannula; NF	omized control wasive ventilati PPV, non-invasi	RCT, randomized controlled trial; NRCT, nonrandomized controlled trial; HFNC, high-flow nasal c standard definition; NR, not reported; NN, non-invasive ventilation; COT, conventional oxygen ti airway pressure; LFNC, low-flow nasal cannula; NPPV, non-invasive positive pressure ventilation	gh-flow nasal car ional oxygen the ire ventilation	nnula; MFNC, med rapy; ECMO, extra	dium-flow nasal c	annula; ICU, intel rane oxygenatio	RCT, randomized controlled trial; NRCT, nonrandomized controlled trial; HFNC, high-flow nasal cannula; MFNC, medium-flow nasal cannula; ICU, intensive care unit; ER, emergency room; IOR, interquartile range; SD, standard definition; NR, not reported; NIV, non-invasive ventilation; COT, conventional oxygen therapy; ECMO, extracorporeal membrane oxygenation; IMV, invasive mechanical ventilation; CPAP, continuous positive airway pressure; LFNC, low-flow nasal cannula; NPV, non-invasive positive pressure ventilation	mergency room; hanical ventilatic	IQR, interquai on; CPAP, conti	tile range; SD, nuous positive

Table 1 (continued)

nit; ER, emergency room; IQR, interquartile range; SD,	sive mechanical ventilation; CPAP, continuous positive	
IC, high-flow nasal cannula; MFNC, medium-flow nasal cannula; ICU, intensive care	ventional oxygen therapy; ECMO, extracorporeal membrane oxygenation; IMV, invasi	ressure ventilation
RCT, randomized controlled trial; NRCT, nonrandomized controlled trial; HFN	tandard definition; NR, not reported; NIV, non-invasive ventilation; COT, con	airway pressure; LFNC, low-flow nasal cannula; NPPV, non-invasive positive p

	Pron	е	Non-pr	one		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 RCT							
Taylor 2021	0	27	0	13		Not estimable	
Fralick 2022	1	126	1	122	0.3%	0.97 [0.06, 15.31]	
Jayakumar 2021	3	30	2	30	0.8%	1.50 [0.27, 8.34]	
Gad 2021	3	15	3	15	1.1%	1.00 [0.24, 4.18]	
Rosén 2021	6	36	3	39	1.3%	2.17 [0.58, 8.03]	
Alhazzani 2022	46	205	46	195	17.3%	0.95 [0.66, 1.36]	
Ibarra-Estrada 2022	71	216	79	214	33.2%	0.89 [0.69, 1.15]	+
Ehrmann 2021	117	564	132	557	46.1%	0.88 [0.70, 1.09]	
Subtotal (95% CI)		1219		1185	100.0%	0.91 [0.78, 1.06]	₩ · · · · · · · · · · · · · · · · · · ·
Total events	247		266				
Heterogeneity: Tau ² = 0	.00; Chi ² :	= 2.24,	df = 6 (P	= 0.90)	I ² = 0%		
Test for overall effect: Z	= 1.26 (P	= 0.21))				
1.1.2 NRS							
Pierucci 2021	0	16	3	16	0.6%	0.14 (0.01, 2.56)	·
Jagan 2020	0	40	16	65	0.6%	0.05 [0.00, 0.79]	
Barker 2021	1	40	4	10	1.2%	0.25 [0.03, 1.86]	
Sryma 2021	2	30	4	15	1.2%		
Koike 2022	2	27	4	31	2.7%	0.25 [0.05, 1.21] 0.43 [0.13, 1.46]	
Prud'homme 2021	5	48	4	48	2.7%	1.50 [0.45, 4.98]	
Tonelli 2021	5	40 38	4	40	4.2%		
Padrão 2020	56	30 57	22	109	4.2%	0.59 [0.23, 1.47]	
	5	40	98		4.7%	0.52 [0.22, 1.21]	
Jouffroy 2021	5			339		0.43 [0.19, 1.00]	
Ferrando 2020 Bahloul 2021	8 7	49 21	17 12	122 17	5.3% 6.2%	1.17 [0.54, 2.54]	
Musso 2022	10	81	59	162	6.9%	0.47 [0.24, 0.93]	
	9	25	59 16	23		0.34 [0.18, 0.63]	
Altinay 2022					7.2%	0.52 [0.29, 0.93]	
Zang 2020	10	23	28	37	8.3%	0.57 [0.35, 0.95]	
Esperatti 2022 Olon 2022	21	187	47	148	8.8%	0.35 [0.22, 0.56]	
Qian 2022	56	239	47	222	10.6%	1.11 [0.79, 1.56]	
Loureiro-Amigo 2022	26	60 505	64 120	103	10.9%	0.70 [0.50, 0.97]	<u>4</u>
Perez-Nieto 2022 Subtotal (95% CI)	100	505 1496	120	322	12.4% 100.0%	0.53 [0.42, 0.67] 0.56 [0.45, 0.70]	▲
Total events	275	1490	586	1005	100.0%	0.50 [0.45, 0.70]	
Heterogeneity: Tau ² = 0		= 35.66		(P = 0 0	105) [.] I ² = f	52%	
Test for overall effect: Z	•		•	. – <u>0.</u> c			
Test for subgroup differ	ences: Cl	hi ^z = 12	.34, df =	1 (P = 0	1.0004), I ²	= 91.9%	Favours prone Favours non-prone
ig. 2 Mortality of non-int	tubated p	atients					
·							

Adverse events


Seven RCTs reported adverse events [11, 12, 22, 25–28]. The incidence of cardiac arrest (at any time) was similar between the prone and non-prone positions (prone vs. non-prone 3/564 vs. 1/557, p value not reported) [22] and skin breakdown and vomiting were also similar between the two groups (moderate certainty of evidence, Additional file 4: Fig. S4). Six NRSs reported adverse events in the prone group [5, 30, 34, 42, 44, 46], which were mainly mild (very low certainty of evidence, Additional file 4: Table S1).

Length of stay in hospital or ICU

Length of stays in hospital or ICU were not different between prone and non-prone groups in both RCTs and NRSs (Additional file 4: Figs. S5, S6).

ICU-free days and ventilator-free days

ICU-free days were not different in RCTs, and ventilatorfree days were not different in RCTs and NRSs between prone and non-prone groups (Additional file 4: Figs. S7, S8).



	Pron	е	Non-pr	one		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
3.22.1 Nasal cannula o	r facial m	ask					
Sryma 2021	2	30	4	15	1.1%	0.25 [0.05, 1.21]	
Padrão 2020	6	57	22	109	3.7%	0.52 [0.22, 1.21]	
Altinay 2022	9	25	16	23	7.7%	0.52 [0.29, 0.93]	
Zang 2020	10	23	28	37	10.6%	0.57 [0.35, 0.95]	
Loureiro-Amigo 2022	26	60	64	103	24.9%	0.70 [0.50, 0.97]	
Perez-Nieto 2022	100	505	120	322	52.1%	0.53 [0.42, 0.67]	
Subtotal (95% CI)		700		609	100.0%	0.57 [0.48, 0.67]	♦
Total events	153		254				
Heterogeneity: Tau ² = 0	1.00; Chi ² =	3.06,	df = 5 (P :	= 0.69)	; l² = 0%		
Test for overall effect: Z	= 6.83 (P	< 0.00	001)				
3.22.2 HFNC or NIV							
Barker 2021	1	10	4	10	3.8%	0.25 [0.03, 1.86]	
Tonelli 2021	5	38	17	76	13.7%	0.59 [0.23, 1.47]	
Jouffroy 2021	5	40	98	339	15.5%	0.43 [0.19, 1.00]	
Ferrando 2020	8	49	17	122	17.1%	1.17 [0.54, 2.54]	
Musso 2022	10	81	59	162	22.0%	0.34 [0.18, 0.63]	
Esperatti 2022	21	187	47	148	27.9%	0.35 [0.22, 0.56]	
Subtotal (95% CI)		405		857	100.0%	0.47 [0.31, 0.71]	\bullet
Total events	50		242				
Heterogeneity: Tau ² = 0	.10; Chi ² =	8.42,	df = 5 (P :	= 0.13)	; I [≈] = 41%		
Test for overall effect: Z	= 3.61 (P	= 0.00	03)				
Test for subgroup differ	rences: Cł	ni² = 0.7	70, df = 1	(P = 0.	40), I ² = 0	%	Favours prone Favours non-prone
in. 4 Subaroup analysis	of mortali	v hv o	waen del	iverv m	ethods in	non-intubated natients	of non-randomized studies
		., ., ., .,	gender	ivery II			

	Pron	е	Non-pr	one		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.2.1 RCT							
Taylor 2021	0	27	0	13		Not estimable	
Gad 2021	3	15	3	15	0.6%	1.00 [0.24, 4.18]	
Jayakumar 2021	4	30	4	30	0.8%	1.00 [0.28, 3.63]	
Rosén 2021	12	36	13	39	3.2%	1.00 [0.53, 1.90]	
Ibarra-Estrada 2022	65	216	92	214	20.4%	0.70 [0.54, 0.90]	-
Alhazzani 2022	70	205	79	195	20.4%	0.84 [0.65, 1.09]	
Ehrmann 2021	185	564	223	557	54.6%	0.82 [0.70, 0.96]	
Subtotal (95% CI)		1093		1063	100.0%	0.81 [0.72, 0.90]	♦
Total events	339		414				
Heterogeneity: Tau ² = 1	0.00; Chi ²	= 1.96	df = 5 (F	e = 0.85); I ² = 0%		
Test for overall effect: 2							
1.2.2 NRS							5.05
Pierucci 2021	2	16	3	16	2.0%	0.67 [0.13, 3.47]	
Sryma 2021	2	30	5	15	2.3%	0.20 [0.04, 0.91]	
Koike 2022	2	27	13	31	2.6%	0.18 [0.04, 0.71]	
Zang 2020	8	23	4	37	3.7%	3.22 [1.09, 9.49]	
Jagan 2020	4	40	18	65	4.0%	0.36 [0.13, 0.99]	20 B B B B B B B B B B B B B B B B B B B
Bahloul 2021	9	21	4	17	4.1%	1.82 [0.68, 4.90]	
Prud'homme 2021	8	48	7	48	4.4%	1.14 [0.45, 2.90]	200 C C C C C C C C C C C C C C C C C C
Numata 2022	5	54	20	54	4.5%	0.25 [0.10, 0.62]	a later and an
Barker 2021	6	10	5	10	5.1%	1.20 [0.54, 2.67]	
Tonelli 2021	7	38	30	76	5.6%	0.47 [0.23, 0.96]	
Musso 2022	8	81	44	162	5.7%	0.36 [0.18, 0.74]	
Altinay 2022	8	25	19	23	6.4%	0.39 [0.21, 0.71]	
Qian 2022	31	258	30	243	7.4%	0.97 [0.61, 1.56]	
Jouffroy 2021	16	40	241	339	8.0%	0.56 [0.38, 0.83]	
Ferrando 2020	22	55	60	144	8.0%	0.96 [0.66, 1.40]	
Esperatti 2022	44	187	79	148	8.6%	0.44 [0.33, 0.59]	
Padrão 2020	33	57	53	109	8.6%	1.19 [0.89, 1.60]	
Perez-Nieto 2022	119	505	130	322	9.1%	0.58 [0.48, 0.72]	-
Subtotal (95% CI)		1515		1859	100.0%	0.65 [0.50, 0.85]	
Total events	334		765				
Heterogeneity: Tau ² = I	•			(P < 0.	.00001); P	² = 74%	
Test for overall effect: 2	Z = 3.17 (F	P = 0.00	02)				
							0.01 0.1 1 10 100
Test for subgroup diffe	rences. C	$hi^2 = 2$	06 df =	1 (P = 0	15) F=	51 5%	Favours prone Favours non-prone
Fig. 5 Need for intubatio						01.070	
rig. > Need for intubatio	n of non-i	ntupat	eu patien	LS			


Intubated group


Only NRSs included intubated patients [9, 38, 45]. Mortality did not differ between the prone and nonprone groups in 2 NRSs [9, 45] (Fig. 8), but 1 NRS [38] reported better survival in prone group than in non-prone group (adjusted hazard ratio 0.282, 95% CI 0.126 to 0.63) (very low certainty of evidence). Incident occurrence of peripheral line removal in two patients during positioning was reported in 1 NRS [9] (very low certainty of evidence, Additional file 4: Table S1). Hospital LOS and ICU LOS were longer in prone group than non-prone group (hospital LOS, one study [9], n = 261, MD 10.1 days, 95% CI 7.39 to 12.81 days, P < 0.00001; ICU LOS, one study [45], n = 734, MD 2.71 days, 95% CI 0.77 to 4.65 days, P = 0.006). Ventilator-free days did not differ between the prone and non-prone groups in 2 NRSs [9, 45] (Additional file 4: Fig. S9), and no studies reported ICU-free days between prone and non-prone groups.


The GRADE summary of findings table of primary outcomes is reported in Table 2.

Discussion

In this analysis, we divided patients with moderate-tosevere COVID-19 into intubated and non-intubated groups and investigated the benefit of the prone position. In summary, we found that prone position reduced the







risk of intubation in non-intubated patients, particularly those supplied with high-flow oxygen systems. However, prone position did not reduce the risk of mortality in both the intubated or non-intubated groups. In nonintubated patients, survival benefit was only observed in observational studies, not in randomized trials. Moreover, there are no randomized controlled trials comparing prone to supine positions in intubated patients. Only a few observational cohort studies were included and did not show statistically better survival. In addition, ventilator-free days were significantly shorter in the prone position group. As a result, there is still insufficient evidence to support the beneficial effect of prone position in intubated patients.

However, it would be considered unethical to assign patients to the non-prone group since large randomized controlled trials and meta-analyses have already shown the beneficial effect of the prone position in patients with moderate and severe non-COVID ARDS [3, 47, 48]. In addition, although two different phenotypes of COVID-19 ARDS have been proposed, several studies have suggested similar clinical features between COVID-19 and non-COVID ARDS [49]. Compliance was higher in the COVID-19 initially, but decreased 3-7 days after onset with no difference from non-COVID-19 ARDS [50]. In addition, pathological characteristics and distribution of compliance were similar among studies of COVID-19 and non-COVID-19 ARDS [51, 52]. They also suggested that treatment previously considered for non-COVID-19 ARDS may apply to COVID-19 patients with respiratory failure [51]. In addition, observational cohort studies demonstrated that improved oxygenation and increased Pao₂/Fio₂ ratio after prone positioning even remained significantly higher after returning to the supine position [9, 53, 54]. Static lung compliance was also increased after prone positioning with reduced driving pressure [54]. In the analysis of lung computed tomography in COVID-19 ARDS, regional hyperinflation decreased, and inflation distribution was more homogenous in the prone position, which was also similar to other ARDS [55]. Based on previous experiences from non-COVID-19 ARDS and improvement of oxygenation in observational studies, guidelines recommended implementing the prone position in intubated patients with COVID-19. Further research is needed to evaluate the effect of prone position in intubated patients.

Meanwhile, studies on awake-prone positioning in non-intubated patients were conducted more actively, including randomized controlled trials. We included the most recently updated trials in this meta-analysis. Among non-intubated patients, the prone position group had a reduced risk of intubation. In the subgroup analysis according to oxygen delivery methods, prone positioning reduced intubation rates only in more severely ill patients receiving a high-flow oxygen system or non-invasive ventilation, and the risk of intubation was similar between the prone and non-prone groups in patients with lowflow oxygen. However, since there were only three randomized trials and a small number of patients included in the low-flow oxygen subgroup, it is insufficient to evaluate the effect of prone position. Therefore, more randomized trials will be needed. There was no difference in the mortality between prone and non-prone groups among randomized trials regardless of oxygen supply methods, which was consistent with previous meta-analysis [10]. There was also no significant difference in the length of ICU and hospital stays between the prone and non-prone groups.

Before COVID-19, there were only a few case series and retrospective observational studies about awake-prone positioning on acute respiratory failure [56–59]. Those studies showed that a prone position improved oxygenation, but a detailed investigation has not been done. Among non-intubated COVID-19 patients, improvement in oxygenation was also observed with prone positioning [5–7]. A physiologic study showed that dead space and shunt were reduced. As a result, V/Q mismatch was improved in the prone position, similar to the mechanism in the intubated patients [60]. Reduced intubation risk might be due to improvement of oxygenation and respiratory mechanics. Nevertheless, mortality rates were similar between the two groups in randomized trials. One

Outcomes	Study design	Study design Anticipated absolute effects ^c (95% Cl)	Relative effect (95% CI)	ict (95% CI)	Nº. of	Certainty of the
		Risk with non-prone	Risk with prone		participants (studies)	evidence (GRADE)
Non-intubated patients	nts					
Mortality	RCT	224 per 1000	204 per 1000 (175–238) RR 0.91 (0.78–1.06)	-1.06)	2404 (8)	OOOO High
	NRS	314 per 1000	176 per 1000 (141–220) RR 0.56 (0.45–0.70)	-0.70)	3361 (18)	OOO Very low ^a
Need for intubation	RCT	389 per 1000	315 per 1000 (280-351) RR 0.81 (0.72-0.90)	-0.90)	2156 (7)	OOOO High
	NRS	412 per 1000	267 per 1000 (206–350) RR 0.65 (0.50–0.85)	-0.85)	3374 (18)	OOO Very low ^a
Adverse events	RCT	24 per 1000	23 per 1000 (16–34) RR 0.97 (0.66–1.43)	-1.43)	7011 (6)	OOO Moderate ^b
	NRS	Cases in the prone group were reported as follows: desaturation or hemodynamic worsening 0/30 [34], back pain 2/30 [34] and 3/57 [42], bloating sensation 2/30 [34], gastric distension and vomit 0/81 [30], peripheral line removal 2/57 [42] and 2/81 [30], nasal skin ulceration 2/81 [30], major adverse events 0/48 [44], overall adverse events 0/17 [5] and 0/38 [45]	emodynamic worsening 0/30 [34], back pa d vomit 0/81 [30], peripheral line removal 2 48 [44], overall adverse events 0/17 [5] and	ain 2/30 2/57 [42] d 0/38 [46]	716 (6)	OOO Very
Intubated patients						
Mortality	NRS	525 per 1000	504 per 1000 (441–573) RR 0.96 (0.84–1.09)	-1.09)	995 (2)	OOO Very low ^a
		Chen et al. [38] reported better survival in prone group than in non-prone group (adjusted hazard ratio 0.282, 95% Cl 0.126 to 0.63)	orone group (adjusted hazard ratio 0.282, 9;	95% CI	40 (1)	
Adverse events	NRS	Cases in the prone group were reported as follows: endotracheal tube dislocation 0/62 [9], peripheral line removal 2/62 [9] 261 (1)	e dislocation 0/62 [9], peripheral line remo	oval 2/62 [<mark>9</mark>]	261 (1)	OOO Very low ^{a,b}
GRADE Working Group grades of evidence	p grades of eviden	Ice				
High certainty: we are	: very confident the	High certainty: we are very confident that the true effect lies close to that of the estimate of the effect				
Moderate certainty: w	/e are moderately σ	Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different	nate of the effect, but there is a possibility that	t it is substanti	ally different	
Low certainty: our cor	nfidence in the effe	Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect	estimate of the effect			
Very low certainty: we	have very little co	Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect	erent from the estimate of effect			
Cl, confidence interval	l; RR, risk ratio; RC1	Cl, confidence interval; RR, risk ratio; RCT, randomized controlled trial; NRS, nonrandomized studies				

Table 2 GRADE summary of findings table of primary outcomes

Cl, confidence interval; RR, risk ratio; RCT, randomized controlled trial; NRS, nonrandomized studies

^a Downgrade for risk-of-bias concern in the domains of possibility of target group comparisons, target group selection, and confounder

^b No more than 300 events

^c The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

suggestion why the mortality benefit was not achieved in the prone position group was low adherence to prone position in the awake-prone groups [37]. The duration of the awake-prone position depended on the patient's effort, unlike when performed in intubated patients, who were usually sedated for prone position. In this analysis, durations were not stated in the studies and, if noted, varied with a median of 5 to 9 h. However, recent studies showed that a longer duration of prone position was associated with better outcomes [11, 22, 31], and Esperatti et al. suggested performing prone position for at least 8 h per day to reduce the risk of mortality [31]. Therefore, there is a possibility that the duration of prone positioning was not sufficient to achieve survival gain. However, other factors affecting the duration of prone position, such as poor medical conditions, also influence survival, so the effect of duration on mortality should be assessed more carefully.

Complications that may occur in the prone position include dislocation of the endotracheal tube and vascular lines, transient hypotension, vomiting, and pressure sores [61]. However, there were no serious adverse events such as unstable hemodynamics and removal of the endotracheal tube both in the intubated and nonintubated patients in our study. The incidence of minor complications was also similar between the two groups. The prone position can be a safe and effective intervention for patients with respiratory failure.

This study had several limitations. First, RCTs were limited to the non-intubated group. Therefore, there is a lack of evidence to evaluate the effect of the prone position in intubated patients. Second, the severity of the included patients varied within and among studies. The oxygen supply method in non-intubated patients was particularly heterogeneous, from the nasal cannula to the high-flow oxygen system and non-invasive ventilation. So we performed subgroup analysis by dividing the studies into two groups: low-flow and high-flow oxygen systems, and found that the reduced risk of intubation was observed only in more severe patients with high-flow oxygen systems or noninvasive ventilation. Third, most studies did not present the cycle and duration of prone positioning or were inconsistent, particularly for non-intubated patients. According to the previous guidelines, there were only recommendations for intubated patients to maintain a prone position for at least 16 h. Further studies to evaluate the effective duration of the prone position in non-intubated patients should be considered, although heterogeneous disease severities and oxygen requirements may make the investigation difficult.

Conclusions

For non-intubated patients with COVID-19, prone positioning reduced the risk of intubation, particularly in patients requiring a high-flow oxygen system. However, the survival benefit was unclear between the prone and non-prone groups. There was insufficient evidence to support the beneficial effects of prone positioning in intubated patients, because only a few observational studies compared prone position and non-prone position. Further well-designed randomized controlled trials will be needed.

Abbreviations

ARDS: Acute respiratory distress syndrome; CI: Confidence interval; COT: Conventional oxygen therapy; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; HFNC: High-flow nasal cannula; ICU: Intensive care unit; IMV: Invasive mechanical ventilation; LOS: Length of stay; MD: Mean differences; NIV: Non-invasive ventilation; NRS: Nonrandomized study; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT: Randomized clinical trial; RoB: Cochrane risk-of-bias tool; RoBANS: Risk of Bias Assessment tool for Nonrandomized studies; RR: Relative risk.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s40001-022-00953-z.

Additional file 1. PRISMA checklists.

Additional file 2. Search strategies.

Additional file 3. List of excluded studies after full-text screening.

Additional file 4. Forest plots, table. Risk of bias of included randomized controlled trials (a, b) and non-randomized studies (c, d), (a) Risk of bias graph of randomized controlled trials: review authors' judgements about each risk of bias item presented as percentages across all included studies. (b) Risk of bias graph of randomized controlled trials: review authors' judgements about each risk of bias item for each included study. (c) Risk of bias graph of non-randomized studies: review authors' judgements about each risk of bias item presented as percentages across all included studies. (d) Risk of bias graph of non-randomized studies; review authors' judgements about each risk of bias item for each included study. Figure S2. Contour-enhanced funnel plot for mortality of non-intubation patients in non-randomized studies. Figure S3. Contour-enhanced funnel plot for intubation rate of non-intubation patients in non-randomized studies. Figure S4 Adverse events in randomized controlled trials Table S1 Adverse events in non-randomized studies. Figure S5. Hospital length of stay of non-intubated patients. Figure S6. ICU length of stay of nonintubated patients. Figure S7. ICU-free days of non-intubated patients in randomized controlled trials. Figure S8. Ventilator-free days of nonintubated patients. Figure S9. Ventilator-free days of intubated patients in non-randomized studies.

Acknowledgements

The authors would like to thank the Korean Academy of Tuberculosis and Respiratory Diseases and the Korean Society of Critical Care Medicine for their contributions to this paper: Suk-Kyung Hong, HakJae Lee, In Seok Jeong, and Jae-Seung Jung.

Author contributions

HJL and JoK contributed equally to this work. Study concept and design: HJL, JoK, and JuK. Literature search and resolving discrepancies: MC. Data extraction and quality assessment of the included studies: WIC and JJ. Data analysis and interpretation: HJL, JoK, WIC, and JJ. Drafting of the manuscript: HJK and JoK. Revising the manuscript: HJL, JoK, and JuK. All authors have read and approved the final manuscript.

Others

This manuscript followed the reporting protocol, especially the PICO or major processes for conducting systematic reviews.

Funding

This research was supported by the National Evidence-based Collaborating Agency (Grant Nos. NP21-004 and NA22-009). The funding sources had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Division of Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, South Korea. ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul, South Korea. ³Division of Pulmonary and Allergy, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Gyeonggi-do, South Korea. ⁴Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Gyeonggi-do, South Korea.

Received: 28 August 2022 Accepted: 14 December 2022 Published online: 27 December 2022

References

- Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Talbot HK, Casey JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.
- Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, Adhikari NKJ, Amato MBP, Branson R, Brower RG, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(9):1253–63.
- Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.
- Fernandez R, Trenchs X, Klamburg J, Castedo J, Serrano JM, Besso G, Tirapu JP, Santos A, Mas A, Parraga M, et al. Prone positioning in acute respiratory distress syndrome: a multicenter randomized clinical trial. Intensive Care Med. 2008;34(8):1487–91.
- Ni Z, Wang K, Wang T, Ni Y, Huang W, Zhu P, Fan T, Wang Y, Wang B, Deng J, et al. Efficacy of early prone or lateral positioning in patients with severe COVID-19: a single-center prospective cohort. Precis Clin Medi. 2020;3(4):260–71.
- Jouffroy R, Darmon M, Isnard F, Geri G, Beurton A, Fartoukh M, Tudesq JJ, Nemlaghi S, Demoule A, Azoulay E, et al. Impact of prone position in non-intubated spontaneously breathing patients admitted to the ICU for severe acute respiratory failure due to COVID-19. J Crit Care. 2021;64:199–204.
- Bahloul M, Kharrat S, Hafdhi M, Maalla A, Turki O, Chtara K, Ammar R, Suissi B, Hamida CB, Chelly H, et al. Impact of prone position on outcomes of COVID-19 patients with spontaneous breathing. Acute Crit Care. 2021;36(3):208–14.
- 8. Loureiro-Amigo J, Suarez-Carantona C, Oriol I, Sanchez-Diaz C, Coloma-Conde A, Manzano-Espinosa L, Rubio-Rivas M, Otero-Perpina

B, Ferreiro-Mazon Jenaro MM, Coduras-Erdozain A et al. Prone position in COVID-19 patients with severe acute respiratory distress syndrome receiving conventional oxygen therapy: a retrospective study. Arch Bronconeumol. 2021;58(3):277–80.

- Shelhamer MC, Wesson PD, Solari IL, Jensen DL, Steele WA, Dimitrov VG, Kelly JD, Aziz S, Gutierrez VP, Vittinghoff E, et al. Prone positioning in moderate to severe acute respiratory distress syndrome due to COVID-19: a cohort study and analysis of physiology. J Intensive Care Med. 2021;36(2):241–52.
- Li J, Luo J, Pavlov I, Perez Y, Tan W, Roca O, Tavernier E, Kharat A, McNicholas B, Ibarra-Estrada M, et al. Awake prone positioning for nonintubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(6):573–83.
- Ibarra-Estrada M, Li J, Pavlov I, Perez Y, Roca O, Tavernier E, McNicholas B, Vines D, Marín-Rosales M, Vargas-Obieta A, et al. Factors for success of awake prone positioning in patients with COVID-19-induced acute hypoxemic respiratory failure: analysis of a randomized controlled trial. Crit Care. 2022;26(1):84.
- Alhazzani W, Parhar KKS, Weatherald J, Al Duhailib Z, Alshahrani M, Al-Fares A, Buabbas S, Cherian SV, Munshi L, Fan E, et al. Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. JAMA. 2022;327(21):2104–13.
- Stilma W, van Meenen DMP, Valk CMA, de Bruin H, Paulus F, Serpa Neto A, Schultz MJ. On Behalf Of The P-CCG: incidence and practice of early prone positioning in invasively ventilated COVID-19 patientsinsights from the PRoVENT-COVID observational study. J Clin Med. 2021;10(20):4783.
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:14651858.
- Kim SY, Seo HJ, Lee YJ, Park JE. Study Design Algorithm for Medical literature of Intervention (DAMI) and Risk of Bias for Nonrandomized Studies (RoBANS) ver 2.0 by HIRA. Seoul: Health Insurance Review & Assessment Service; 2013. p. 65–6.
- Kim S, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408–14.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
- Collaboration TC: Review Manager (RevMan), 5.4 edn. The Cochrane Collaboration; 2020.
- 20. Team RC. R: a language and environment for statistical computing. 4.2.1. Vienna: R Foundation for Statistical Computing; 2020.
- Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.
- Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, Roca O, Mirza S, Vines D, Garcia-Salcido R, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9(12):1387–95.
- Fralick M, Colacci M, Munshi L, Venus K, Fidler L, Hussein H, Britto K, Fowler R, da Costa BR, Dhalla I, et al. Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE). BMJ. 2022;376:e068585.
- Gad GS. Awake prone positioning versus non invasive ventilation for COVID-19 patients with acute hypoxemic respiratory failure. Egypt J Anaesth. 2021;37(1):85–90.
- 25. Jayakumar D, Ramachandran P, Rabindrarajan E, Vijayaraghavan BKT, Ramakrishnan N, Venkataraman R. Standard Care versus awake prone position in adult nonintubated patients with acute hypoxemic respiratory failure secondary to COVID-19 infection-a multicenter feasibility randomized controlled trial. J Intensive Care Med. 2021;36(8):918–24.

- Kharat A, Dupuis-Lozeron E, Cantero C, Marti C, Grosgurin O, Lolachi S, Lador F, Plojoux J, Janssens JP, Soccal PM, et al. Self-proning in COVID-19 patients on low-flow oxygen therapy: a cluster randomised controlled trial. ERJ Open Res. 2021;7(1):00692–2020.
- Rosén J, von Oelreich E, Fors D, Jonsson Fagerlund M, Taxbro K, Skorup P, Eby L, Campoccia Jalde F, Johansson N, Bergström G, et al. Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial. Crit Care. 2021;25(1):209.
- Taylor SP, Bundy H, Smith WM, Skavroneck S, Taylor B, Kowalkowski MA. Awake prone positioning strategy for nonintubated hypoxic patients with COVID-19: a pilot trial with embedded implementation evaluation. Ann Am Thorac Soc. 2021;18(8):1360–8.
- Qian ET, Gatto CL, Amusina O, Dear ML, Hiser W, Buie R, Kripalani S, Harrell FE Jr, Freundlich RE, Gao Y, et al. Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial. JAMA Intern Med. 2022;182(6):612–21.
- 30. Musso G, Taliano C, Molinaro F, Fonti C, Veliaj D, Torti D, Paschetta E, Castagna E, Carbone G, Laudari L, et al. Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-tosevere hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study. Crit Care. 2022;26(1):118.
- 31. Esperatti M, Busico M, Fuentes NA, Gallardo A, Osatnik J, Vitali A, Wasinger EG, Olmos M, Quintana J, Saavedra SN, et al. Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study. Crit Care (Lond, Engl). 2022;26(1):16.
- 32. Ferrando C, Mellado-Artigas R, Gea A, Arruti E, Aldecoa C, Adalia R, Ramasco F, Monedero P, Maseda E, Tamayo G, et al. Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study. Crit Care. 2020;24(1):597.
- Pierucci P, Ambrosino N, Di Lecce V, Dimitri M, Battaglia S, Boniello E, Portacci A, Resta O, Carpagnano GE. Prolonged active prone positioning in spontaneously breathing non-intubated patients With COVID-19-associated hypoxemic acute respiratory failure with PaO(2)/FiO(2) >150. Front Med. 2021;8:626321.
- Sryma P, Mittal S, Mohan A, Madan K, Tiwari P, Bhatnagar S, Trikha A, Dosi R, Bhopale S, Viswanath R, et al. Effect of proning in patients with COVID-19 acute hypoxemic respiratory failure receiving noninvasive oxygen therapy. Lung India. 2021;38(7 Supplement 1):S6–10.
- Zang X, Wang Q, Zhou H, Liu S, Xue X. Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study. Intensive Care Med. 2020;46(10):1927–9.
- Altinay M, Sayan I, Turk HS, Cinar AS, Sayın P, Yucel T, Islamoglu S, Ozkan MT, Cetiner I. Effect of early awake prone positioning application on prognosis in patients with acute respiratory failure due to COVID-19 pneumonia: a retrospective observational study. Braz J Anesthesiol. 2022;72(2):194–9.
- Barker J, Pan D, Koeckerling D, Baldwin AJ, West R. Effect of serial awake prone positioning on oxygenation in patients admitted to intensive care with COVID-19. Postgrad Med J. 2021;98(1159):360–4.
- Chen Y, Zhang J, Feng H, Wan F, Zhang Y, Tan L. Prone positioning in intubated and mechanically ventilated patients with SARS-CoV-2. J Clin Anesth. 2021;71:110258.
- Jagan N, Morrow LE, Walters RW, Klein LP, Wallen TJ, Chung J, Plambeck RW. The positioned study: prone positioning in nonventilated coronavirus disease 2019 patients—a retrospective analysis. Crit Care Explor. 2020;2(10): e0229.
- 40. Koike T, Hamazaki N, Kuroiwa M, Kamiya K, Otsuka T, Sugimura K, Nishizawa Y, Sakai M, Miida K, Matsunaga A, et al. Detailed changes in oxygenation following awake prone positioning for non-intubated patients with COVID-19 and hypoxemic respiratory failure—a historical cohort study. Healthcare (Basel, Switzerland). 2022;10(6):1006.
- Numata K, Kobayashi D, Hosoda T, Saito Y, Minoura A, Yamazaki S, Fujitani S. Efficacy of awake prone positioning for severe illness coronavirus disease 2019 patients: a propensity score-adjusted cohort study. Acute Med Surg. 2022;9(1): e734.
- 42. Padrão EMH, Valente FS, Besen B, Rahhal H, Mesquita PS, de Alencar JCG, da Costa MGP, Wanderley APB, Emerenciano DL, Bortoleto FM, et al. Awake prone positioning in COVID-19 hypoxemic respiratory failure:

exploratory findings in a single-center retrospective cohort study. Acad Emerg Med. 2020;27(12):1249–59.

- 43. Perez-Nieto OR, Escarraman-Martinez D, Guerrero-Gutierrez MA, Zamarron-Lopez El, Mancilla-Galindo J, Kammar-Garcia A, Martinez-Camacho MA, Deloya-Tomas E, Sanchez-Diaz JS, Macias-Garcia LA, et al. Awake prone positioning and oxygen therapy in patients with COVID-19: The APRONOX study. Eur Respir J. 2021;15:15.
- 44. Prud'homme E, Trigui Y, Elharrar X, Gaune M, Loundou A, Lehingue S, Boyer A, Lefebvre L, Dols AM, Chanez P, et al. Effect of prone positioning on the respiratory support of nonintubated patients with COVID-19 and acute hypoxemic respiratory failure: a retrospective matching cohort study. Chest. 2021;160(1):85–8.
- 45. Stilma W, van Meenen DMP, Valk CMA, de Bruin H, Paulus F, Serpa Neto A, Schultz MJ. On behalf of the P-CCG: incidence and practice of early prone positioning in invasively ventilated COVID-19 patients-insights from the PROVENT-COVID observational study. J Clin Med. 2021;10(20):19.
- 46. Tonelli R, Pisani L, Tabbì L, Comellini V, Prediletto I, Fantini R, Marchioni A, Andrisani D, Gozzi F, Bruzzi G, et al. Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: a retrospective multicenter cohort study. Pulmonology. 2021.
- Mancebo J, Fernández R, Blanch L, Rialp G, Gordo F, Ferrer M, Rodríguez F, Garro P, Ricart P, Vallverdú I, et al. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;173(11):1233–9.
- Beitler JR, Shaefi S, Montesi SB, Devlin A, Loring SH, Talmor D, Malhotra A. Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: a meta-analysis. Intensive Care Med. 2014;40(3):332–41.
- Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, Hernández M, Gea A, Arruti E, Aldecoa C, Martínez-Pallí G, Martínez-González MA, Slutsky AS, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020;46(12):2200–11.
- Beloncle F, Studer A, Seegers V, Richard JC, Desprez C, Fage N, Merdji H, Pavlovsky B, Helms J, Cunat S, et al. Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome. Crit Care. 2021;25(1):248.
- Goligher EC, Ranieri WM, Slutsky AS. Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter? Intensive Care Med. 2021;47(1):83–5.
- Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37(4):749–76.
- Weiss TT, Cerda F, Scott JB, Kaur R, Sungurlu S, Mirza SH, Alolaiwat AA, Kaur R, Augustynovich AE, Li J. Prone positioning for patients intubated for severe acute respiratory distress syndrome (ARDS) secondary to COVID-19: a retrospective observational cohort study. Br J Anaesth. 2021;126(1):48–55.
- Roy A, Behera S, Pande A, Bhattacharjee A, Bhattacharyya A, Baidya DK, Anand RK, Ray BR, Subramaniam R, Maitra S. Physiological effect of prone positioning in mechanically ventilated SARS-CoV-2- infected patients with severe ARDS: an observational study. J Anaesthesiol Clin Pharmacol. 2022;38(Suppl 1):S120-s124.
- Protti A, Santini A, Pennati F, Chiurazzi C, Ferrari M, Iapichino GE, Carenzo L, Dalla Corte F, Lanza E, Martinetti N, et al. Lung response to prone positioning in mechanically-ventilated patients with COVID-19. Crit Care. 2022;26(1):127.
- Valter C, Christensen AM, Tollund C, Schønemann NK. Response to the prone position in spontaneously breathing patients with hypoxemic respiratory failure. Acta Anaesthesiol Scand. 2003;47(4):416–8.
- Feltracco P, Serra E, Barbieri S, Persona P, Rea F, Loy M, Ori C. Non-invasive ventilation in prone position for refractory hypoxemia after bilateral lung transplantation. Clin Transplant. 2009;23(5):748–50.
- Feltracco P, Serra E, Barbieri S, Milevoj M, Michieletto E, Carollo C, Rea F, Zanus G, Boetto R, Ori C. Noninvasive high-frequency percussive ventilation in the prone position after lung transplantation. Transplant Proc. 2012;44(7):2016–21.
- Scaravilli V, Grasselli G, Castagna L, Zanella A, Isgrò S, Lucchini A, Patroniti N, Bellani G, Pesenti A. Prone positioning improves oxygenation in spontaneously breathing nonintubated patients with hypoxemic acute respiratory failure: a retrospective study. J Crit Care. 2015;30(6):1390–4.

- Liu L, Xie J, Wang C, Zhao Z, Chong Y, Yuan X, Qiu H, Zhao M, Yang Y, Slutsky AS. Prone position improves lung ventilation-perfusion matching in non-intubated COVID-19 patients: a prospective physiologic study. Crit Care. 2022;26(1):193.
- Gattinoni L, Taccone P, Carlesso E, Marini JJ. Prone position in acute respiratory distress syndrome. Rationale, indications, and limits. Am J Respir Crit Care Med. 2013;188(11):1286–93.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

